AVT33 (pembrolizumab biosimilar) / Alvotech, JAMP Pharma - LARVOL DELTA

Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care (GlobeNewswire) - "Alvotech...and the JAMP Pharma Group...announced today that the companies have expanded their exclusive partnership to commercialize biosimilars developed and manufactured by Alvotech, by adding two biosimilar candidates from Alvotech’s pipeline: AVT16 a biosimilar for an immunology product and AVT33, a biosimilar for an oncology product....Alvotech will be responsible for the development and commercial supply of the biosimilar candidates. In exchange for milestone payments and future sales royalties, JAMP Pharma will receive exclusive rights to commercialize Alvotech’s biosimilars in Canada, leveraging JAMP Pharma’s strong sales, marketing capabilities and experience in successfully commercializing new biosimilars in the fast-growing Canadian market."

Licensing / partnership • Immunology • Oncology